ClinicalTrials.gg
CompletedNCT05673603Updated Apr 18, 2023

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

A Phase 1 interventional study of Brensocatib in Renal Impairment, sponsored by Insmed Incorporated. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Jul 2021, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
267th of 468
28 · median 32
Started
2021
with 21 others
Phase 1
232 of 553
14 open now
Registered
478th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 267th largest by enrollment of the 468 interventional ones that give a count, is one of 22 that started in 2021, is one of 232 in phase 1, and was the 478th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine the pharmacokinetics (PK) following a single oral dose administration of brensocatib, safety, and tolerability of brensocatib when administered to participants with impaired renal function and in healthy participants.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Brensocatib
  • INS1007
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Has a (BMI) 18 to 35 kilograms per square meter (kg/m\^2), inclusive, and a body weight of ≥50 kg at Screening.

Inclusion Criteria (for Participants With Renal Impairment):

  • Mild, moderate, or severe renal impairment as determined by estimated (eGFR) and calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
  • Renal insufficiency or other related concomitant medical conditions (e.g., hypertension, anemia) has remained stable for at least 3 months before study drug dosing.

Inclusion Criteria for Healthy Participants:

  • Normal renal function as determined by eGFR and calculated using the CKD-EDI formula, or by 24-hour urine (CLcr) corrected for body size.
  • In good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12-lead (ECG) results, and physical examination findings.

Exclusion Criteria:

  • Positive test result for types 1 or 2 antibodies, virus antibodies, or surface antigen or hepatitis B core antibodies.
  • History of relevant drug and/or food allergies (i.e., allergy to brensocatib or any , or any significant food allergy).
  • The participant has received study drug in another study within 30 days of Screening.

Exclusion Criteria (for Participants With Renal Impairment):

  • Has nephrotic syndrome, defined as urine dipstick 4+ for protein and plasma albumin \<3.0 grams per deciliter (g/dL), and then confirmed if proteinuria >5 g/day.
  • Has an extrarenal cause of renal impairment (e.g., rapidly growing, space occupying lesions, adrenal enlargement).
  • Has a functioning renal transplant (participant may be included in the study if he or she had a failed renal transplant and is not taking ).
  • Has a value less than 8.5 g/dL.
  • Has Type 1 or Type 2 diabetes mellitus.

Exclusion Criteria (for Healthy Participants):

  • Has used any prescription (excluding hormonal , hormone replacement therapy, nonsteroidal anti-inflammatory drugs, or acetaminophen) or over-the-counter medications, including herbal or nutritional supplements, within 14 days before study drug dosing and throughout the study.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Mild Impairment): Brensocatib

    Participants with mild renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.

    Drug: Brensocatib

  • Experimental
    Cohort 2 (Moderate Impairment): Brensocatib

    Participants with moderate renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.

    Drug: Brensocatib

  • Experimental
    Cohort 3 (Severe Impairment): Brensocatib

    Participants with severe renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.

    Drug: Brensocatib

  • Experimental
    Cohort 4 (Normal): Brensocatib

    Healthy participants with normal renal function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with renal impairment.

    Drug: Brensocatib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time Curve (AUC) of Brensocatib

    Pharmacokinetics of brensocatib following a single dose will be assessed in participants with renal impairment and in healthy participants.

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 14

  2. Maximum Observed Plasma Concentration (Cmax) of Brensocatib

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 14

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Brensocatib

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 14

  4. Number of Participants who Experienced at Least one Adverse Event (AE)

    Determination of the safety and tolerability of a single dose of brensocatib in participants with impaired renal function and in healthy participants.

    Time frame: Up to Day 14

07

Study locations

3 sites
  • USA002
    Orlando, Florida 32809, United States
  • USA003
    Tampa, Florida 33603, United States
  • USA001
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2023, 18 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 18 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 6, 2023
StartActual
Jul 20, 2021
Primary completionActual
Feb 14, 2023
CompletionActual
Feb 14, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05673603
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Jul 20, 2021
Primary completion
Feb 14, 2023
Completion
Feb 14, 2023
Last update
Apr 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion